3D Systems (DDD) Q1 2026 Earnings Transcript

3D Systems reported Q1 revenue of $95.5 million, up 11% year over year, with Healthcare Solutions rising 21% to $50.1 million and Industrial Solutions up 1.6% to $45.4 million. Non-GAAP gross margin improved to 36.1% and adjusted EBITDA turned positive at $2.1 million, while non-GAAP loss per share narrowed to $0.01 from $0.21. Management guided Q2 revenue to $93 million-$95 million and adjusted EBITDA to a $2 million-$4 million loss, citing seasonality and macro caution despite strong momentum in dental, med tech, and aerospace & defense.

Analysis

DDD is trying to convert a cyclical demand rebound into an earnings inflection, but the important shift is not the headline EBITDA beat — it is the mix change toward regulated, high-switching-cost end markets. Once healthcare and dental become a larger share of the base, revenue quality improves, pricing friction rises, and the business becomes less hostage to capex freezes in discretionary industrial verticals. That creates a more durable path to leverage than the market has historically assigned to the name.

The second-order effect is competitive: by refreshing the portfolio during the downcycle, DDD may have widened the performance gap versus smaller additive peers that cut R&D to protect margins. If the current product cycle sustains, the company can pressure incumbents in dental labs and surgical planning workflows before those channels fully normalize, because regulatory approvals and workflow integration create stickier adoption than typical printer sales. The Littleton expansion is also a tell that internal throughput, not demand, may become the gating factor in aerospace/defense over the next 2-3 quarters.

The bear case is that Q1 likely benefited from timing and mix, while Q2 guidance explicitly bakes in seasonality and macro caution; that leaves the stock vulnerable if healthcare volume normalizes more sharply than management expects or if Middle East logistics continue to disrupt shipments. The key risk window is the next 30-90 days: if order conversion at NextDent and A&D does not translate into a visibly stronger backlog, the market will fade the “turnaround” narrative and re-anchor on low-margin manufacturing economics. The more interesting contrarian read is that DDD may be exiting the trough earlier than consensus, but the valuation multiple still has to prove it can sustain positive EBITDA through a softer second quarter.

Key Decisions for Investors

• Go long DDD on a 6-12 month horizon, but only on pullbacks after the next quarter's guide reset; the setup is asymmetric if dental backlog converts and A&D capacity expansion starts showing through, but near-term volatility remains high.
• Pair trade: long DDD / short a weaker additive manufacturing peer with less healthcare exposure and less balance-sheet flexibility; the thesis is that regulated end markets will separate survivors from commoditized printer vendors over the next 2-4 quarters.
• For more tactical exposure, buy DDD calls 3-6 months out only if shares fade on Q2 seasonality concerns; upside catalyst is proof that EBITDA stays positive despite the seasonal trough, while downside is limited if the product cycle is real.
• Avoid chasing the stock after sharp post-earnings rallies; the cleaner entry is when the market doubts the sustainability of the mix shift and price action reverts before the next backlog update.
• If you want a lower-beta expression, use a partial long DDD against a short basket of discretionary industrial capex names that depend on broad manufacturing recovery; DDD’s healthcare/dental mix should hold up better if macro growth softens.